By 2026, Bangladesh has firmly positioned itself as one of Asia’s fastest‑growing pharmaceutical and medical device markets. The pharmaceutical industry now meets nearly 98% of domestic demand, with the market size surpassing USD 6 billion, while exports continue to expand to more than 150 countries, including highly regulated destinations such as the US and Europe. Between July 2024 and February 2025 alone, pharmaceutical exports generated USD 134.15 million, marking a 13% year‑on‑year rise, and this momentum has carried forward into 2026. The medical device sector, valued at USD 442 million in 2021, has flourished at a 13% annual growth rate, crossing USD 800 million by 2025 and continuing its upward trajectory. Imports of medical devices are growing at a CAGR of around 10%—significantly higher than the global industry average of 4–6%—underscoring the country’s strong healthcare demand and modernization drive. With generics maintaining over 85% market share, government initiatives such as the API policy 2018 and the establishment of a dedicated API Park are attracting USD 1 billion in planned investment by 2032, aiming to reduce import reliance and create 500,000 new jobs. These figures highlight why Bangladesh is not only self‑sufficient in pharmaceuticals but also a rising global hub, making it the ideal host for international exhibitions that bring together innovators, investors, and industry leaders to tap into one of the most dynamic healthcare markets in Asia.